24Apr
23Jan
Interview with Ziad Moukheiber of Boston Harbor Angels
Interview with Ziad Moukheiber of Boston Harbor Angels by ChatGPT Interview with Ziad Moukheiber, President of Boston Harbor Angels, on Angel Investing in 2024 **Interviewer:** Welcome, Ziad. It's a pleasure to have you here to discuss the evolving landscape of angel investing in 2024. **Ziad Moukheiber:** Thank you for having me. It's an exciting time in the angel investing world. **Interviewer:** To start, could you explain what angel investing looks like in 2024, particularly any major changes or trends? **Moukheiber:** Absolutely. In 2024, angel investing has...
22May
Boston Harbor Angels Screening Meeting!
For 20 years the Boston Harbor Angels screening meeting has taken place once a month to review applicants for consideration. The flow of entrepreneurs taking a risk to launch their business, their idea or their science and technology has not stopped and the entrepreneurship drive is felt every month. Thank you to the screening committees over the years and also to the entrepreneurs putting everything on the line. #founders #startups #entrepreneurs #investingforabetterworld www.bostonharborangels.com
28Apr
Never A Dull Moment Podcast “Best Of”
Never A Dull Moment Podcast with Ziad and his guests releases a "Best Of" the first 10 episodes. New episodes with more guests, talk shows and startups to come soon!
13Feb
Matchmaking service Tawkify picks up ‘anti-superficial’ dating app S’More in mobile expansion
Matchmaking service provider Tawkify announced today it acquired S’More, an “anti-superficial” dating app that had experimented with blurred profile photos, and even blurred video chats, in an attempt to get people to get to know one another without the focus on physical appearance. With the acquisition, S’More is sunsetting its app, and founder Adam Cohen-Aslatei will instead join the Tawkify team to lead the launch of its first-ever mobile product. Deal terms were not disclosed, but S’More had raised $3.2 million in seed funding, according to Crunchbase. Set...
04Nov
Pyramid Biosciences to Present at the 2022 Jefferies London Healthcare Conference
Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, announced today that Chief Executive Officer, Brian Lestini, M.D., Ph.D., will present at the 2022 Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 2:40 PM GMT. Read more >>
02Nov
Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, today announced top-line clinical results for its Phase II COVID-19 “universal” booster vaccine, AKS-452. An interim analysis of the data found that 93% of subjects previously vaccinated with Pfizer, Moderna, Johnson & Johnson (Janssen), and AstraZeneca vaccines showed an increase in neutralizing antibody titers after receiving a single dose of AKS-452. The average neutralization titers across all subjects increased 4-fold against the Wuhan strain and 5-fold against the Omicron...
28Oct
Legally blind man can see 20/20 vision again and inspires others with his story
More than 280,000 Ohioans are considered legally blind. Luckily for some, there are medical devices available to help correct their vision. Aside from it being extremely expensive getting a pair of these glasses, which is through the company, 'eSight', Benjamin Murray explained being legally blind comes with a long list of challenges in itself. "You know, it's hard to think about everyday life when you can't see," 33-year-old Murray said. He was considered legally blind for 26 years. In 2015,...
26Oct
U.S. Senator Richard Blumenthal (D-CT) Tours Landsdowne Labs
“Children swallow button batteries. That’s the reality of our world. Because the batteries become loose from devices, and then can literally burn through the throat of a young child. It happens again and again…[leading to] years of treatment, surgery, and therapy.” So said U.S. Senator Richard Blumenthal, D-CT, on an October 7 visit to Landsdowne Labs, at Fairfield University, in Fairfield, CT. Link to video of remarks. Landsdowne has since received a patent for technology that rapidly reduces chemical reactions...
24Oct